JEMPERLI may help your immune system fight cancer

JEMPERLI is not chemotherapy or radiation. It is an immunotherapy (IH-myoo-noh-THAYR-uh-pee), which means it is designed to work with the body’s immune system to find and attack cancer cells.

Understanding immunotherapy

Here’s how JEMPERLI is designed to work with the body to help fight cancer:

Cancer cells can hide from your immune system

Hidden cancer cellsCancer cells can hidefrom your immune system. Cells are then able to grow and spread

down-arrow
JEMPERLI prevents cancer cells from hiding

Exposed cancer cellsJEMPERLI may prevent cancer cells from hidingso your immune system can find and attack them

Treatment with JEMPERLI in combination with the chemotherapy medicines, carboplatin and paclitaxel

If you have been diagnosed with dMMR/MSI-H* endometrial cancer that has spread outside your uterus (advanced) or your cancer has returned, your doctor may determine that JEMPERLI in combination with carboplatin and paclitaxel is appropriate for you.

*dMMR/MSI-H stands for “mismatch repair deficiency/microsatellite instability-high.” These are important biomarkers in endometrial cancer that can help your doctor decide if JEMPERLI is appropriate for you.

This treatment approach:

Puzzle pieces icon

Combines 2 types of medicine that work in different ways

Shield icon

Uses JEMPERLI, which is designed to work with the body’s immune system to fight cancer cells

Arrow targeting tumor icon

Adds carboplatin and paclitaxel for the first 6 doses to directly attack your tumor and help reduce its size

Together, JEMPERLI plus carboplatin and paclitaxel may help attack and shrink your tumor.

Light bulb icon

Good to know

If your doctor prescribes JEMPERLI in combination with carboplatin and paclitaxel, you will be given this combination for the first 6 doses of your treatment before receiving JEMPERLI alone.

Find Out More

Bar graph icon

JEMPERLI study results

Want to learn how JEMPERLI may help?

See Study Results

IV bag icon

How is JEMPERLI given?

When starting any treatment, it’s natural to have questions about what you may expect—like how JEMPERLI is given.

Get the Details

Download icon

Resources for you

Knowledge is power. That's why we're committed to providing you with educational resources to help you stay informed along your treatment journey.

Go to Resources

Related FAQs

  • How has JEMPERLI been studied?

    Researchers have conducted clinical trials to study the effectiveness, risks, and side effects associated with JEMPERLI. Clinical trials are still ongoing to evaluate the effectiveness, risks, and side effects of JEMPERLI.

  • Is advanced or returned endometrial cancer common?

    About 1 in 4 people with endometrial cancer has cancer that has spread outside the uterus (advanced) or has returned.

  • What is a biomarker?

    A biomarker (BY-oh-MAR-ker) is a molecule found in the tissues or fluids of your body that shows if a condition, process, or disease is normal or abnormal. Endometrial cancer may have a biomarker known as dMMR (mismatch repair deficiency). Testing for this biomarker can help your doctor decide if JEMPERLI is right for you.